## Piet Geusens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6007464/publications.pdf Version: 2024-02-01



DIET CELISENS

#	Article	IF	CITATIONS
1	Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. New England Journal of Medicine, 2001, 344, 333-340.	13.9	1,831
2	Risk of New Vertebral Fracture in the Year Following a Fracture. JAMA - Journal of the American Medical Association, 2001, 285, 320.	3.8	1,561
3	Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 3104-3112.	6.7	510
4	Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, The, 2018, 391, 230-240.	6.3	373
5	Epidemiology of fractures in the United Kingdom 1988–2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone, 2016, 87, 19-26.	1.4	286
6	Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis. New England Journal of Medicine, 2006, 355, 675-684.	13.9	196
7	Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Annals of the Rheumatic Diseases, 2009, 68, 1839-1842.	0.5	164
8	Fracture Liaison Service: Impact on Subsequent Nonvertebral Fracture Incidence and Mortality. Journal of Bone and Joint Surgery - Series A, 2014, 96, e29.	1.4	149
9	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes and Endocrinology,the, 2018, 6, 445-454.	5.5	148
10	A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 191-198.	0.2	146
11	Performance of Risk Indices for Identifying Low Bone Density in Postmenopausal Women. Mayo Clinic Proceedings, 2002, 77, 629-637.	1.4	138
12	Inflammatory diseases and bone fragility. Osteoporosis International, 2017, 28, 3301-3314.	1.3	132
13	Osteoporosis, frailty and fracture: implications for case finding and therapy. Nature Reviews Rheumatology, 2012, 8, 163-172.	3.5	130
14	EULAR/EFORT recommendations for management of patients older than 50â€years with a fragility fracture and prevention of subsequent fractures. Annals of the Rheumatic Diseases, 2017, 76, 802-810.	0.5	111
15	Osteoimmunology and osteoporosis. Arthritis Research and Therapy, 2011, 13, 242.	1.6	110
16	Contributors to Secondary Osteoporosis and Metabolic Bone Diseases in Patients Presenting with a Clinical Fracture. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1360-1367.	1.8	110
17	Musculoskeletal Effects of the Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1593-1599.	1.8	108
18	Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatology International, 2006, 26, 234-239.	1,5	107

#	Article	IF	CITATIONS
19	Risk of new clinical fractures within 2Âyears following a fracture. Osteoporosis International, 2006, 17, 348-354.	1.3	106
20	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16â€weeks of treatment: the CareRA trial. Annals of the Rheumatic Diseases, 2015, 74, 27-34.	0.5	106
21	The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 225-233.	1.2	105
22	Osteoporosis and vertebral fractures in ankylosing spondylitis. Current Opinion in Rheumatology, 2007, 19, 335-339.	2.0	104
23	NSAIDs and fracture healing. Current Opinion in Rheumatology, 2013, 25, 524-531.	2.0	103
24	High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nature Reviews Rheumatology, 2014, 10, 304-313.	3.5	103
25	Denosumab Versus Risedronate in Glucocorticoidâ€Induced Osteoporosis: Final Results of a Twentyâ€Four–Month Randomized, Doubleâ€Blind, Doubleâ€Dummy Trial. Arthritis and Rheumatology, 2019, 71, 1174-1184.	2.9	102
26	Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1623-1628.	0.5	95
27	Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Annals of the Rheumatic Diseases. 2017. 76. 511-520.	0.5	92
28	Bone and Fall-Related Fracture Risks in Women and Men with a Recent Clinical Fracture. Journal of Bone and Joint Surgery - Series A, 2008, 90, 241-248.	1.4	90
29	Effect of Alendronate on the Age-Specific Incidence of Symptomatic Osteoporotic Fractures. Journal of Bone and Mineral Research, 2005, 20, 971-976.	3.1	86
30	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. Journal of Bone and Mineral Research, 2018, 33, 783-794.	3.1	84
31	The relationship among history of falls, osteoporosis, and fractures in postmenopausal women. Archives of Physical Medicine and Rehabilitation, 2002, 83, 903-906.	0.5	83
32	Occupational cadmium exposure and calcium excretion, bone density, and osteoporosis in men. Journal of Bone and Mineral Research, 2010, 25, 1441-1445.	3.1	80
33	Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporosis International, 2015, 26, 2479-2489.	1.3	78
34	Clinical vertebral fractures in patients with ankylosing spondylitis. Journal of Rheumatology, 2004, 31, 1981-5.	1.0	76
35	Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas, 1991, 13, 155-162.	1.0	73
36	Assessment of Individual Fracture Risk: FRAX and Beyond. Current Osteoporosis Reports, 2010, 8, 131-137.	1.5	73

3

#	Article	IF	CITATIONS
37	Secukinumab for Longâ€Term Treatment of Psoriatic Arthritis: A Twoâ€Year Followup From a Phase III, Randomized, Doubleâ€Blind Placeboâ€Controlled Study. Arthritis Care and Research, 2017, 69, 347-355.	1.5	72
38	Determinants of hyperkyphosis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, 65, 770-774.	0.5	71
39	Timing of Subsequent Fractures after an Initial Fracture. Current Osteoporosis Reports, 2010, 8, 118-122.	1.5	71
40	Effect of Secukinumab on Patientâ€Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis and Rheumatology, 2016, 68, 2901-2910.	2.9	63
41	The epidemiology of osteoporosis and fractures in ankylosing spondylitis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 287-292.	1.2	61
42	Osteoporosis and osteoarthritis. Current Opinion in Rheumatology, 2016, 28, 97-103.	2.0	61
43	Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3205-3214.	1.8	61
44	Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology, 2008, 47, 1219-1222.	0.9	57
45	Population-Wide Impact of Non-Hip Non-Vertebral Fractures on Mortality. Journal of Bone and Mineral Research, 2017, 32, 1802-1810.	3.1	51
46	Assessment of the healing process in distal radius fractures by high resolution peripheral quantitative computed tomography. Bone, 2014, 64, 65-74.	1.4	47
47	Integrating a Gender Dimension into Osteoporosis and Fracture Risk Research. Gender Medicine, 2007, 4, S147-S161.	1.4	44
48	Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Archives of Osteoporosis, 2017, 12, 58.	1.0	44
49	A simple clinical score for estimating the long-term risk of fracture in post-menopausal women. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 673-682.	0.2	43
50	The prevalence of vertebral fractures in spondyloarthritis: relation to disease characteristics, bone mineral density, syndesmophytes and history of back pain and trauma. Arthritis Research and Therapy, 2015, 17, 294.	1.6	43
51	Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Rheumatology, 2019, 58, 2284-2294.	0.9	42
52	Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. International Journal of Clinical Practice, 2006, 60, 1394-1400.	0.8	41
53	Impact of guideline implementation by a fracture nurse on subsequent fractures and mortality in patients presenting with non-vertebral fractures. Injury, 2011, 42, S39-S43.	0.7	40
54	Increased fracture risk in patients with type 2 diabetes mellitus: An overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas, 2014, 79, 265-274.	1.0	39

#	Article	IF	CITATIONS
55	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5â€year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatology, 2020, 2, 18-25.	0.9	39
56	Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Research and Therapy, 2009, 11, 251.	1.6	38
57	Serum 25(OH)D response to vitamin D3 supplementation: A meta-regression analysis. Nutrition, 2014, 30, 975-985.	1.1	38
58	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Research and Therapy, 2015, 17, 97.	1.6	38
59	Optimal Use of Vitamin D When Treating Osteoporosis. Current Osteoporosis Reports, 2011, 9, 36-42.	1.5	37
60	Osteoporosis and the Growth Hormone-Insulin-Like Growth Factor Axis. Hormone Research in Paediatrics, 2002, 58, 49-55.	0.8	35
61	Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskeletal Disorders, 2008, 9, 109.	0.8	35
62	Individualizing fracture risk prediction. Maturitas, 2010, 65, 143-148.	1.0	33
63	High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis. Journal of Rheumatology, 2001, 28, 1856-61.	1.0	32
64	Fracture Repair in the Distal Radius in Postmenopausal Women: A Follow-Up 2 Years Postfracture Using HRpQCT. Journal of Bone and Mineral Research, 2016, 31, 1114-1122.	3.1	31
65	Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. Nature Clinical Practice Rheumatology, 2008, 4, 240-248.	3.2	29
66	Timing and risk factors for clinical fractures among postmenopausal women: a 5-year prospective study. BMC Medicine, 2006, 4, 24.	2.3	28
67	Calcium and vitamin D supplementation: state of the art for daily practice. Food and Nutrition Research, 2014, 58, 21796.	1.2	28
68	Fracture liaison programs. Best Practice and Research in Clinical Rheumatology, 2019, 33, 278-289.	1.4	28
69	The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus, 2019, 3, e10211.	1.3	28
70	Emerging treatments for postmenopausal osteoporosis – focus on denosumab. Clinical Interventions in Aging, 2009, 4, 241.	1.3	27
71	Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture. Current Opinion in Rheumatology, 2014, 26, 430-439.	2.0	27
72	The utility of absolute risk prediction using FRAX® and Garvan Fracture Risk Calculator in daily practice. Maturitas, 2014, 77, 174-179.	1.0	27

#	Article	IF	CITATIONS
73	Influence of physical mobility and season on 25-hydroxyvitamin D-parathyroid hormone interaction and bone remodelling in the elderly. European Journal of Endocrinology, 2000, 143, 673-679.	1.9	26
74	Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology, 2007, 46, 1667-1671.	0.9	26
75	Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment. Current Osteoporosis Reports, 2009, 7, 12-17.	1.5	26
76	Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis. Journal of Bone and Mineral Research, 2019, 34, 2001-2011.	3.1	26
77	Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporosis International, 2019, 30, 817-828.	1.3	26
78	Review and evaluation of the Dutch guidelines for osteoporosis. Journal of Evaluation in Clinical Practice, 2006, 12, 539-548.	0.9	25
79	Assessment of Cortical Interruptions in the Finger Joints of Patients With Rheumatoid Arthritis Using HR-pQCT, Radiography, and MRI. Journal of Bone and Mineral Research, 2018, 33, 1676-1685.	3.1	25
80	Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opinion on Biological Therapy, 2009, 9, 649-657.	1.4	23
81	Early Changes in Bone Density, Microarchitecture, Bone Resorption, and Inflammation Predict the Clinical Outcome 12 Weeks After Conservatively Treated Distal Radius Fractures: An Exploratory Study. Journal of Bone and Mineral Research, 2014, 29, 2065-2073.	3.1	23
82	Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis. Rheumatology, 2016, 55, 1431-1436.	0.9	23
83	Vascular channels in metacarpophalangeal joints: a comparative histologic and high-resolution imaging study. Scientific Reports, 2017, 7, 8966.	1.6	23
84	Consensus approach for 3D joint space width of metacarpophalangeal joints of rheumatoid arthritis patients using high-resolution peripheral quantitative computed tomography. Quantitative Imaging in Medicine and Surgery, 2020, 10, 314-325.	1.1	23
85	Review of guidelines for testing and treatment of osteoporosis. Current Osteoporosis Reports, 2003, 1, 59-65.	1.5	22
86	Bone erosions in rheumatoid arthritis. Rheumatology, 2014, 53, 4-5.	0.9	21
87	Fracture prevention in COPD patients; a clinical 5-step approach. Respiratory Research, 2015, 16, 32.	1.4	21
88	New insights into treatment of osteoporosis in postmenopausal women: FigureÂ1. RMD Open, 2015, 1, e000051.	1.8	21
89	Prospective Follow-Up of Cortical Interruptions, Bone Density, and Micro-structure Detected on HR-pQCT: A Study in Patients with Rheumatoid Arthritis and Healthy Subjects. Calcified Tissue International, 2019, 104, 571-581.	1.5	20
90	Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study. European Journal of Endocrinology, 2013, 169, 597-604.	1.9	19

#	Article	IF	CITATIONS
91	Fracture liaison services: do they reduce fracture rates?. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 157-164.	1.2	19
92	Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. Journal of Clinical Investigation, 2008, 118, 2979-85.	3.9	19
93	The Phenotype of Patients with a Recent Fracture: A Literature Survey of the Fracture Liaison Service. Calcified Tissue International, 2017, 101, 248-258.	1.5	18
94	An automated algorithm for the detection of cortical interruptions and its underlying loss of trabecular bone; a reproducibility study. BMC Medical Imaging, 2018, 18, 13.	1.4	18
95	The role of the Fracture Liaison Service (FLS) in subsequent fracture prevention in the extreme elderly. Aging Clinical and Experimental Research, 2019, 31, 1105-1111.	1.4	18
96	Performance of statistical models of shape and appearance for semiautomatic segmentations of spinal vertebrae T4–L4 on digitized vertebral fracture assessment images. Spine Journal, 2015, 15, 1248-1254.	0.6	16
97	Distal radius plate of CFR-PEEK has minimal effect compared to titanium plates on bone parameters in high-resolution peripheral quantitative computed tomography: a pilot study. BMC Medical Imaging, 2017, 17, 18.	1.4	16
98	An automated algorithm for the detection of cortical interruptions on high resolution peripheral quantitative computed tomography images of finger joints. PLoS ONE, 2017, 12, e0175829.	1.1	16
99	Effect of a Cast on Short-Term Reproducibility and Bone Parameters Obtained from HR-pQCT Measurements at the Distal End of the Radius. Journal of Bone and Joint Surgery - Series A, 2016, 98, 356-362.	1.4	15
100	Impact of Systematic Implementation of a Clinical Case Finding Strategy on Diagnosis and Therapy of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2008, 23, 812-818.	3.1	14
101	Visual detection of cortical breaks in hand joints: reliability and validity of high-resolution peripheral quantitative CT compared to microCT. BMC Musculoskeletal Disorders, 2016, 17, 271.	0.8	14
102	Cognitive decline is associated with an accelerated rate of bone loss and increased fracture risk in women: a prospective study from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research, 2021, 36, 2106-2115.	3.1	14
103	Feasibility of rigid 3D image registration of high-resolution peripheral quantitative computed tomography images of healing distal radius fractures. PLoS ONE, 2017, 12, e0179413.	1.1	14
104	Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. Therapeutics and Clinical Risk Management, 2008, Volume 4, 337-344.	0.9	13
105	Heterogeneity of Cortical Breaks in Hand Joints of Patients with Rheumatoid Arthritis and Healthy Controls Imaged by High-resolution Peripheral Quantitative Computed Tomography. Journal of Rheumatology, 2016, 43, 1914-1920.	1.0	13
106	Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporosis International, 2016, 27, 1227-1238.	1.3	13
107	Newer drug treatments: Their effects on fracture prevention. Best Practice and Research in Clinical Rheumatology, 2005, 19, 983-989.	1.4	12
108	The Reliability of a Semi-automated Algorithm for Detection of Cortical Interruptions in Finger Joints on High Resolution CT Compared to MicroCT. Calcified Tissue International, 2017, 101, 132-140.	1.5	12

#	Article	IF	CITATIONS
109	Reliability of HR-pQCTÂDerived Cortical Bone Structural Parameters When Using Uncorrected Instead of Corrected Automatically Generated Endocortical Contours in a Cross-Sectional Study: The Maastricht Study. Calcified Tissue International, 2018, 103, 252-265.	1.5	12
110	Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporosis International, 2020, 31, 1935-1942.	1.3	12
111	Strategies for treatment to prevent fragility fractures in postmenopausal women. Best Practice and Research in Clinical Rheumatology, 2009, 23, 727-740.	1.4	11
112	Clinical fractures cluster in time after initial fracture. Maturitas, 2010, 67, 339-342.	1.0	11
113	The Effect of Bolus Vitamin D3 Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR-pQCT. Journal of Bone and Mineral Research, 2020, 36, 1492-1501.	3.1	11
114	Improved Detection of Scaphoid Fractures with High-Resolution Peripheral Quantitative CT Compared with Conventional CT. Journal of Bone and Joint Surgery - Series A, 2020, 102, 2138-2145.	1.4	11
115	Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988397.	1.2	10
116	A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly. Journal of Bone and Mineral Research, 2020, 35, 1923-1934.	3.1	10
117	Fracture prevention in men. Nature Reviews Rheumatology, 2009, 5, 497-504.	3.5	9
118	OsteoRheumatology: a new discipline?. RMD Open, 2015, 1, e000083.	1.8	9
119	On epidemiology of fractures and variation with age and ethnicity. Bone, 2016, 93, 230-231.	1.4	9
120	The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. Journal of the American Medical Directors Association, 2020, 21, 811-816.	1.2	9
121	Measuring metacarpal cortical bone by digital x-ray radiogrammetry: a step forward?. Arthritis Research and Therapy, 2009, 11, 127.	1.6	8
122	Vertebral fractures in women aged 50 years and older with clinical risk factors for fractures in primary care. Maturitas, 2011, 70, 74-79.	1.0	8
123	Structural damage and inflammation on radiographs or magnetic resonance imaging are associated with cortical interruptions on high-resolution peripheral quantitative computed tomography: a study in finger joints of patients with rheumatoid arthritis and healthy subjects. Scandinavian Journal of Rheumatology, 2018, 47, 431-439.	0.6	8
124	Development of a scoring method to visually score cortical interruptions on high-resolution peripheral quantitative computed tomography in rheumatoid arthritis and healthy controls. PLoS ONE, 2018, 13, e0200331.	1.1	8
125	Cardiovascular Risk Factor Analysis in Patients with a Recent Clinical Fracture at the Fracture Liaison Service. BioMed Research International, 2014, 2014, 1-8.	0.9	7
126	Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma. Osteoporosis International, 2015, 26, 2039-2042.	1.3	7

#	Article	IF	CITATIONS
127	High-resolution peripheral quantitative CT in rheumatology. Nature Reviews Rheumatology, 2015, 11, 123-123.	3.5	7
128	<i>The Emperor's New Clothes</i> : What Randomized Controlled Trials Don't Cover. Journal of Bone and Mineral Research, 2018, 33, 1394-1396.	3.1	7
129	Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Archives of Osteoporosis, 2019, 14, 10.	1.0	7
130	Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone, 2020, 130, 115113.	1.4	7
131	Bone Microarchitecture and Distal Radius Fracture Pattern Complexity. Journal of Orthopaedic Research, 2019, 37, 1690-1697.	1.2	6
132	The use of pulse-echo ultrasound in women with a recent non-vertebral fracture to identify those without osteoporosis and/or a subclinical vertebral fracture: a pilot study. Archives of Osteoporosis, 2020, 15, 56.	1.0	6
133	Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone, 2022, 154, 116209.	1.4	6
134	Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. Journal of Bone and Mineral Research, 2020, 37, 1136-1146.	3.1	6
135	Spinal fractures in ankylosing spondylitis: prevalence, prevention and management. International Journal of Clinical Rheumatology, 2013, 8, 597-608.	0.3	5
136	Contra-lateral bone loss at the distal radius in postmenopausal women after a distal radius fracture: A two-year follow-up HRpQCT study. Bone, 2017, 101, 245-251.	1.4	5
137	Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial. Calcified Tissue International, 2020, 106, 646-654.	1.5	5
138	The risk of new fragility fractures in patients with chronic kidney disease and hip fracture—a population-based cohort study in the UK. Osteoporosis International, 2020, 31, 1487-1497.	1.3	5
139	Femoral Neck Trabecular Microstructure in Ovariectomized Ewes Treated With Calcitonin: MRI Microscopic Evaluation. , 2005, 20, 125.		5
140	The Prevalence of Celiac Disease in a Fracture Liaison Service Population. Calcified Tissue International, 2020, 107, 327-334.	1.5	4
141	Associations between bone attenuation and prevalent vertebral fractures on chest CT scans differ with vertebral fracture locations. Osteoporosis International, 2021, 32, 1869-1877.	1.3	4
142	Association between bone shape and the presence of a fracture in patients with a clinically suspected scaphoid fracture. Journal of Biomechanics, 2021, 128, 110726.	0.9	4
143	Osteoporosis: clinical features. Minerva Medica, 2008, 99, 167-75.	0.3	4
144	Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada. Clinical and Experimental Rheumatology, 2015, 33, 537-44.	0.4	4

#	Article	IF	CITATIONS
145	The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study. Osteoporosis International, 2018, 29, 329-337.	1.3	3
146	Teriparatide vs risedronate for osteoporosis â $\in$ " Authors' reply. Lancet, The, 2018, 391, 1896.	6.3	3
147	Secondary fracture prevention: Drug treatment, fall prevention and nutrition requirements. Best Practice and Research in Clinical Rheumatology, 2019, 33, 290-300.	1.4	3
148	SAT0410â€Secukinumab Improves Physical Function and Quality of Life in Patients with Active Ankylosing Spondylitis: 2-Year Data from Measure 1, A Phase 3 Randomised Trial. Annals of the Rheumatic Diseases, 2016, 75, 818.1-818.	0.5	2
149	The Role of the Immune System in the Development of Osteoporosis and Fracture Risk. , 2016, , 187-214.		2
150	Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS). Osteoporosis International, 2017, 28, 2867-2876.	1.3	2
151	Osteoporose en fractuurpreventie. , 2013, , 215-226.		2
152	Effect of High-Dose Once-Yearly Bolus of Oral Vitamin D on Falls and Fractures in Older Women. Current Osteoporosis Reports, 2010, 8, 115-117.	1.5	1
153	The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 130.	1.6	1
154	A Case Report of Abnormal Fracture Healing as Detected With High-Resolution Peripheral Quantitative Computed Tomography. Journal of Clinical Densitometry, 2017, 20, 486-489.	0.5	1
155	Complementarity of Cohort Studies and Randomized Controlled Trials. Journal of Bone and Mineral Research, 2019, 34, 1769-1770.	3.1	1
156	Comments on Kanis et al.: Characteristics of recurrent fractures. Osteoporosis International, 2019, 30, 529-530.	1.3	1
157	How to implement guidelines and models of care. Best Practice and Research in Clinical Rheumatology, 2022, , 101759.	1.4	1
158	Response to Boonen etÂal. â€~Assessing the relative efficacy of different osteoporosis agents based on the outcomes from meta-analyses'. International Journal of Clinical Practice, 2008, 62, 165-166.	0.8	0
159	Comment on: Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis: reply. Rheumatology, 2008, 47, 1108-1109.	0.9	0
160	Glucocorticoid-induced osteoporosis: An indication for anabolic therapy. Current Osteoporosis Reports, 2009, 7, 71-72.	1.5	0
161	THU0398â€Most Patients with a Recent Fracture after the Age of 50 Years are not Predicted to be at High Risk: The Fracture Prevention Paradox. Annals of the Rheumatic Diseases, 2013, 72, A300.1-A300.	0.5	0
162	AB0742â€Intravenous Loading and Subcutaneous Maintenance with Secukinumab Provides Sustained Improvement in Multiple Measures of Disease Activity in Subjects with Active Ankylosing Spondylitis: 52-Week Data From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Measure 1 Study. Annals of the Rheumatic Diseases, 2015, 74, 1146.3-1147.	0.5	0

#	Article	IF	CITATIONS
163	SAT0263â€The Prevalence of Vertebral Fractures in Spondyloarthropathies: Relation to Disease Characteristics, Bone Mineral Density, Syndesmophytes and History of Back Pain and Trauma. Annals of the Rheumatic Diseases, 2015, 74, 754.1-754.	0.5	0
164	FRI0470â€EFFECT OF DISCONTINUATION OF DENOSUMAB IN SUBJECTS WITH RHEUMATOID ARTHRITIS TREA™ WITH GLUCOCORTICOIDS. , 2019, , .	TED	0
165	FRIO467â€THE DISTRIBUTION OF PREVALENT AND INCIDENT VERTEBRAL FRACTURES IN THE TERIPARATIDE VERSUS RISEDRONATE "VERO―CLINICAL TRIAL. , 2019, , .		0
166	Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Useâ€: Journal of Clinical Endocrinology and Metabolism, 2020, 105, e903-e904.	1.8	0
167	OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis. Journal of the Endocrine Society, 2020, 4, .	0.1	0
168	Diagnostic Approach. , 2010, , 565-575.		0
169	AB0292â€Autoantibodies to a novel peptide uh-ra.1 are associated with disease remission in rheumatoid arthritis. , 2018, , .		0
170	OP0345â€Denosumab compared with risedronate in glucocorticoid-treated subjects: results from the final 24-month analysis of a randomised, double-blind, double-dummy study. , 2018, , .		0
171	FRIO640â€Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis in three large independent cohorts. , 2018, , .		0
172	OR13-03 Understanding Why Older People with Low Trauma Fractures Die Prematurely. Journal of the Endocrine Society, 2020, 4, .	0.1	0
173	Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect. Journal of Bone and Mineral Research, 2020, 37, 1075-1076.	3.1	Ο